Treventis Corporation is a biotechnology company focused on developing small molecule therapeutics that target protein misfolding in neurodegenerative diseases. The company's proprietary platform enables the design of molecules that prevent the aggregation of tau protein in Alzheimer's disease and alpha-synuclein in Parkinson's disease.
Treventis's lead program is T-2300, a small molecule designed to inhibit tau protein aggregation. Tau tangles are one of the hallmark pathological features of Alzheimer's disease, and their spread correlates with cognitive decline[1].
A parallel program targeting alpha-synuclein aggregation in Parkinson's disease and related synucleinopathies[1:1].
Tau protein is a microtubule-associated protein that plays a critical role in maintaining neuronal structure and function. In Alzheimer's disease and other tauopathies, tau becomes hyperphosphorylated, leading to its misfolding and aggregation into neurofibrillary tangles (NFTs)[2]. These tangles are one of the two classic hallmarks of Alzheimer's disease pathology, with the other being amyloid-beta plaques.
The progression of tau pathology follows a predictable pattern in the brain, beginning in the entorhinal cortex and spreading to the hippocampus and other cortical regions[3]. This spread correlates strongly with cognitive decline, making tau an attractive therapeutic target.
The tau protein is encoded by the MAPT gene located on chromosome 17q21.31. Alternative splicing produces six isoforms in the adult human brain, ranging from 352 to 441 amino acids in length. The microtubule-binding repeat domains (R1-R4) are crucial for tau's physiological function and are also involved in pathological aggregation[4].
Emerging evidence suggests that soluble tau oligomers, rather than mature fibrils, represent the most toxic species in Alzheimer's disease[5]. These oligomers are believed to:
This understanding has shifted the therapeutic paradigm from targeting mature tangles to preventing the formation and propagation of oligomeric tau species.
Several strategies for targeting tau pathology have been explored, including:
Treventis's approach focuses on aggregation inhibitors, which offer several advantages over other strategies[6]:
Alpha-synuclein is a natively unfolded protein that plays a central role in Parkinson's disease pathology. In PD, alpha-synuclein misfolds and aggregates into Lewy bodies, which are found in dopaminergic neurons of the substantia nigra and throughout the brain[8].
The prion-like propagation of alpha-synuclein aggregates is thought to underlie disease progression, similar to tau pathology in AD. Strategies to inhibit alpha-synuclein aggregation could therefore provide disease-modifying benefits in PD.
Treventis's platform targets the fundamental mechanism of protein misfolding that underlies many neurodegenerative diseases. Unlike antibody approaches that target extracellular proteins, Treventis's small molecules can penetrate cells and target intracellular protein aggregates[2:1].
Key advantages:
The company's technology enables development of molecules that can recognize similar structural motifs in different misfolded proteins, potentially allowing for pan-aggregation inhibitors[6:1].
Treventis's small molecules are designed to:
This multi-pronged approach distinguishes Treventis from single-mechanism competitors and may provide superior therapeutic efficacy.
Treventis uses computational approaches to design small molecules that:
The company's drug discovery platform integrates:
Treventis's candidates are validated in:
| Company | Compound | Target | Stage | Status |
|---|---|---|---|---|
| TauRx | LMTX/Methylene blue | Tau aggregation | Phase 3 | Completed[9] |
| Biogen | BIIB080 (Ionis) | Tau ASO | Phase 2 | Active |
| AbbVie | ABBV-8E12 | Anti-tau antibody | Phase 1/2 | Completed |
| Eli Lilly | LY3303560 | Anti-tau antibody | Phase 2 | Active |
| Treventis | T-2300 | Tau aggregation | Preclinical | IND-enabling |
Bloom GS. Amyloid-beta and tau: the мятеж and the reality of Alzheimer's disease. Trends in Neurosciences. 2020. ↩︎ ↩︎
Braak H, et al. Neurofibrillary changes of the human tau protein: from early to advanced stages. Acta Neuropathologica. 2020. ↩︎
Mandelkow EM, Mandelkow E. Tau in physiology and pathology. Nature Reviews Neuroscience. 2021. ↩︎
Sato C, et al. Tau oligomers as pathogenic seeds in Alzheimer's disease. Journal of Alzheimer's Disease. 2021. ↩︎
Avasthy S, et al. Small molecule inhibitors of tau aggregation: a potential therapeutic strategy for Alzheimer's disease. Journal of Medicinal Chemistry. 2022. ↩︎ ↩︎
Pardridge WM. Blood-brain barrier delivery of protein and antibody therapeutics. Drug Discovery Today. 2021. ↩︎
Bridi JC, et al. Alpha-synuclein aggregation in Parkinson's disease. Frontiers in Molecular Neuroscience. 2022. ↩︎
Wischik CM, et al. Tau aggregation inhibitor therapy for Alzheimer's disease. Expert Opinion on Investigational Drugs. 2021. ↩︎